肖战回头笑

【券商聚焦】高盛维持上海医药(02607)“沽售”评级 微升目标价至10.3元并上调净利润预测_城市资讯网

及资产减值。该行将其2026至2027年净利润预测分别上调5.8%及1.7%，以反映销售开支增加及上海和黄药业的合并，引入2028年每股盈利预测1.06元；目标价由10.03港元上调至10.3港元，维持“沽售”评级。

    评论          发表

d her values and how she lived her life.“As much as we wanted to save my mother, we also wanted her to help other patients,” her daughter, Park Da-bin, said in a statement. “Even though we were not fi

并，引入2028年每股盈利预测1.06元；目标价由10.03港元上调至10.3港元，维持“沽售”评级。

当前文章：http://n77rli.kuailianvpnf.com.cn/np4g/ftb42.html

发布时间：09:53:45